Background: Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio. The generic brand for this drug is still not available in Indonesia. We aimed to compare the efficacy between the generic drug and its innovator (Exjade®) by a study of bioequivalence in Indonesia among healthy volunteers. Methods: An open-label, single-dose, two-sequence, randomized two-way crossover study with one-week wash-out period was evaluated in 28 enrolled volunteers. Blood samples were collected up to 60 hours following drug administration. Deferasirox level was determined by HPLC method with ultraviolet detector. The pharmacokinetic parameters tested for bioequivalence assessment were AUC0-t, AUC0-∞, and Cmax. Results: The 90% confidence intervals obtained by analysis of variance for AUC0-t, AUC0-∞, and Cmax were 83.04%-95.53%, 83.18%-98.88%, and 81.67%-105.47%, respectively. These results were all within the range of 80.00-125.00%. Conclusion: Our results indicated that a single dose of 500 mg Deferasirox tablet demonstrated similar bioequivalence in terms of rate and extent of absorpstion to single dose of Exjade® 500 mg tablet.
|Number of pages||6|
|Journal||Iranian Journal of Blood and Cancer|
|Publication status||Published - Jun 2021|
- Iron chelation
- Thalassemia major